Clearmind Medicine To Pioneer Psychedelic Clinical Trials For Alcohol Use Disorder With Ivy League Universities
Portfolio Pulse from Benzinga Newsdesk
Clearmind Medicine Inc. has entered into a Clinical Trial Agreement with Johns Hopkins University School of Medicine and Yale University to conduct Phase I/IIa clinical trials of its proprietary MEAI-based CMND-100 as a potential treatment for Alcohol Use Disorder (AUD). The trial will evaluate the tolerability, safety, and pharmacokinetics of CMND-100 in healthy subjects and those with AUD, and its efficacy in reducing drinking patterns and cravings.
November 09, 2023 | 2:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clearmind Medicine is conducting clinical trials for its AUD treatment, CMND-100, in partnership with Johns Hopkins and Yale. This could potentially boost the company's reputation and value if the trials are successful.
The news of Clearmind Medicine entering into a Clinical Trial Agreement with prestigious institutions like Johns Hopkins and Yale for its AUD treatment, CMND-100, is likely to be seen positively by investors. If the trials are successful, it could lead to increased demand for the company's shares, potentially driving up the stock price in the short term.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100